Greenwich LifeSciences Inc, a Phase 3 biotech developing immunotherapies for breast cancer, has filed Amendment No. 1 to Form S-1 Registration Statement on June 23, 2020 with the U.S. Securities and Exchange Commission and announced terms for its IPO.
The company plans to raise $21 million by offering 2.7 million shares at a price range of $7.50 to $8.50. Assuming a successful IPO at the midpoint of the proposed price range, the company's market value at IPO would approximate $106 million.
The Stafford, Texas-based company was founded in 2006 is planning to commence a Phase 3 trial in 2020. The company is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery.
It plans to list on the Nasdaq Capital Market under the symbol “GLSI.” Aegis Capital Corp. is the underwriter of the IPO.
The company engages Sheppard, Mullin, Richter & Hampton LLP as US Securities Counsel, and MaloneBailey, LLP as Independent Auditor.
#ipo #nasdaq #GreenwichLifeSciences #breastcanserprevention #healthcare
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].
